Late acuteness: p53 protein controls molecular crossroads in glucose metabolic pathway

The gene for the protein p53 is the most oft-times mutated in child cancer. It encodes a tumor suppressor, and traditionally researchers sooner a be wearing assumed that it acts chiefly as a regulator of how genes are made into proteins. Under, researchers at the University of Pennsylvania Votaries of Panacea pretension that the protein has at least identical other biochemical activity: controlling the metabolism of the sugar glucose, a certain of carcass's primary sources of fuel. These brand-new insights on a well-studied protein may be used to occur renewed cancer therapies.

Xiaolu Yang, PhD, associate professor of Cancer Biology at the Abramson One's own flesh Cancer Research Institute, along with Mian Wu, PhD, at the University of Sphere and Technology of China and Nanjing University, announcement in the current emanation of Nature Apartment Biology that p53 controls a molecular crossroads in the apartment's glucose metabolic pathway.

They originate tha t p53 physically binds to and inhibits an enzyme -- glucose-6-phosphate dehydrogenase (G6PD), which catalyzes the start revatio impression of the pathway. If p53 can't do its intended assignment, cells burgeon absent from of control.

Blocking this pathway shunts glucose away from vitality storage and to making genetic structure blocks and lipids that donate to cells' proliferation. p53 normally serves to dull synthesis of molecules and apartment twin by forcing the stall to put into place up less glucose.

In tumors, more than half of which succeed mutations in the p53 gene, this routing duty is abolished, enabling cells to build biomass and split with abandon.

The findings demand a biochemical elucidation destined for the Warburg outcome, which explains how cancer cells, regardless of type, have all the hallmarks inevitably to support their glucose consumption, but not in an energy efficient wa y.

We start a connection between the most frequently mutated gene in cancer cells and how that transfiguration contributes to tumor vegetation, says Yang.

Yang and his rig found in both humane colon cancer cells and fibroblast cells from mouse embryos that collapse of p53 leads to increased glucose consumption in spite of the energy unqualified pathway. This augment was associated with greater lipid composite and increased activity of G6PD, the enzyme that p53 is imagined to latch onto to shunt glucose into storage, not wild synthesis.

The pair base that p53 binds when to G6PD to check its vocation, ostensibly by interfering with the aptitude of G6PD to mode a molecular complex. In comparison, p53 mutants dearth this binding activity. In potency, demonstrating the binding duty of p53 is distinct from its business as a regulator of protein transcription.

Intriguingly, Yang and his line-up determine that the flush of p53 is only here 3 percent that of G6PD. So in the room, the p53/G6PD proportion is uncommonly low. But p53 has a thespian potency on the entire activity of G6PD. This suggests that one p53 molecule can inactivate many G6PD molecules. This qualifies p53 as a catalyst. It appears to statute almost as an enzyme to proselytize its much more replete binding partner into an pacific form via momentary choose than solid interactions.

Normally, when solitary protein binds to and inhibits another, that inhibition lasts lone as extended as the two proteins are resolved together; breakup of the complex wellnigh invariably activates the released proteins. But in the case of p53 and G6PD, transient interaction with p53 is sufficient to transform G6PD into an inactive form - a hallmark that is most again associated with enzymes. Says Yang, this enables p53, which at most is for the time being at 10 percent the excess of G6PD, to order its binding partner.

Close converting G6PD from lively to dormant build, p53 also has an enzymatic r“le of, says Yang. That big-hearted of structure, he says, is utterly new on the side of p53, and a brand-new paradigm for signal transduction in general.

This non-stoichiometric to all intents of p53 on G6PDH is intriguing as it proposes a catalytic role exchange for p53, something that steady in the p53 unbelievable, which is traditional to special twists, is surprising, wrote Eyal Gottlieb of Cancer Research UK in an accompanying editorial.

Now, says Yang, the puzzle is whether this new situation seeking p53 can be exploited to yield untried anticancer therapies. Once, he says, people were faltering to butt the disorganized pathway because they thought it was stimulatory. Our data suggests the pathway is a satisfactory target.

The digging was supported not later than the China Citizen Natural Proficiency Bottom, the Chinese Elders of the church of Realm and Technology, the Chinese Academy of Sciences, the US Popular Cance r Institute and the US Determined of Defense. Peng Jiang, PhD, and Wenjing Du, PhD, postdoctoral fellows in the Yang lab, were co-first authors on the paper.

Rise: University of Pennsylvania Seminary of Medication

When it takes up glucose, a cell has three choices: It can store the sugar, prevent it into puissance, or operation it to walk away nucleic acids and lipids. As Yang explains, researchers be struck by recognized in return years that tumor cells gobble up glucose far faster than non-cancerous cells, but also that they don't appear to usage the most strength economic pathway to set on fire the fuel. What, then, were they doing with it?